• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
TANG Yuting,SHEN Ying.ACAT1/2 promote resistance of non-small cell lung cancer to KRAS G12C inhibitor[J].Journal Of Pharmaceutical Research,2026,45(5):481-487,541[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 1549times   Download 841次 QR Code for this article
Scan with your phone!
ACAT1/2促进非小细胞肺癌对KRAS G12C抑制剂耐药
汤于婷,沈瑛
Font:Larger+|Default|Smaller-
(上海交通大学医学院药理学与化学生物学系,上海 200025)
摘要:
目的 探讨酰基辅酶A:胆固醇酰基转移酶1/2(ACAT1/2)在KRAS G12C抑制剂获得性耐药中的作用,为逆转非小细胞肺癌(NSCLC)对该类药物的耐药提供潜在靶点。方法 通过大剂量药物冲击法构建Sotorasib获得性耐药细胞;采用免疫印迹法检测ACAT1和ACAT2在亲本和耐药细胞中的蛋白表达水平;采用ACAT1/2抑制剂Avasimibe处理细胞,通过CCK-8法检测细胞活力,评估Avasimibe单药对亲本及耐药细胞增殖的抑制作用,并进一步考察Avasimibe联合Sotorasib对耐药细胞药物敏感性的影响,通过协同系数分析两药的相互作用。结果 成功构建Sotorasib获得性耐药细胞,与亲本细胞相比,H358SoR和H2122SoR对Sotorasib的半数抑制浓度(IC50)显著增加。免疫印迹证实耐药细胞中ACAT1和ACAT2蛋白水平均明显升高。Avasimibe可剂量依赖性抑制亲本及耐药细胞增殖,且对耐药细胞的抑制作用显著强于亲本细胞。联合用药实验中,Avasimibe与Sotorasib联用部分恢复耐药细胞对Sotorasib的敏感性;协同系数分析表明,在多个浓度组合下,两药的协同系数(CI)均小于1,显示出协同抑制的效果。结论 ACAT1和ACAT2在KRAS G12C抑制剂获得性耐药NSCLC细胞中表达上调,靶向ACAT1/2可选择性抑制耐药细胞增殖并部分恢复药物敏感性。ACAT1/2可能通过调控胆固醇代谢参与耐药形成,联合抑制ACAT1/2有望成为克服KRAS G12C抑制剂耐药的新策略。
关键词:  酰基辅酶A:胆固醇酰基转移酶1  酰基辅酶A:胆固醇酰基转移酶2  KRAS G12C抑制剂  获得性耐药  非小细胞肺癌  代谢编程
DOI:10.13506/j.cnki.jpr.2026.05.001
基金项目:国家自然科学基金面上项目(No.82473936)
Received Date:March 09, 2026   Revision Date:March 26, 2026   Publication Date:May 29, 2026
ACAT1/2 promote resistance of non-small cell lung cancer to KRAS G12C inhibitor
TANG Yuting,SHEN Ying
(Department of Pharmacology and Chemical Biology, Shanghai Jiaotong University School of Medicine, Shanghai 200025,China)
Abstract:
Objective To investigate the role of acetyl-CoA: cholesterol acetyltransferase 1/2 (ACAT1/2) in acquired resistance to KRAS G12C inhibitors and to provide a potential target for reversing resistance in non-small cell lung cancer (NSCLC). Methods Sotorasib-resistant cell were established by high-dose drug exposure. Protein expression levels of ACAT1 and ACAT2 were detected by Western blotting. Cells were treated with the ACAT1/2 inhibitor Avasimibe, and cell viability was assessed using the CCK-8 assay to evaluate the inhibitory effect of Avasimibe alone on the proliferation of parental and resistant cells. The effect of Avasimibe in combination with Sotorasib on the drug sensitivity of resistant cells was further examined, and the drug interaction was analyzed using the combination index (CI). Results Sotorasib-resistant cell lines were successfully established, showing significantly increased half maximal inhibitory concentration (IC50) values for Sotorasib compared to parental cells. Western Blot confirmed markedly elevated protein levels of both ACAT1 and ACAT2 in resistant cells. Avasimibe inhibited the proliferation of both parental and resistant cells in a dose-dependent manner, with significantly stronger inhibitory effects observed in resistant cells. In combination experiments, Avasimibe partially restored the sensitivity of resistant cells to Sotorasib. Combination index analysis showed CI values less than 1 across multiple concentration combinations, indicating synergistic inhibitory effects. Conclusion ACAT1 and ACAT2 are upregulated in NSCLC cells with acquired resistance to KRAS G12C inhibitors. Targeting ACAT1/2 selectively inhibits the proliferation of resistant cells and partially restores drug sensitivity. ACAT1/2 may contribute to resistance formation by regulating cholesterol metabolism, and combined inhibition of ACAT1/2 represents a potential strategy to overcome resistance to KRAS G12C inhibitors.
Key words:  Acetyl-CoA:Cholesterol acetyltransferase 1(ACAT1)  ACAT2  KRAS G12C inhibitor  Acquired resistance  Non-small cell lung cancer
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.